Showing 1331-1340 of 1644 results for "".
- Valbenazine Reduced Chorea Associated With Huntington Diseasehttps://practicalneurology.com/news/valbenazine-reduced-chorea-associated-with-huntington-disease/2469775/In a phase 3 study (NCT04102579), participants with Huntington disease (HD) treated with valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA) had a reduction in chorea severity. Chorea re
- No Association Proven to Link Strep Throat and Neurologic Ticshttps://practicalneurology.com/news/no-association-proven-to-link-strep-throat-and-neurologic-tics/2469496/A study published in Neurology found no correlation between increased tic activity after getting strep throat. “The link between streptococcus and tics in children is st
- Insomnia May Be Associated With Increased Risk of Cognitive Impairmenthttps://practicalneurology.com/news/insomnia-may-be-associated-with-increased-risk-of-cognitive-impairment/2469389/A study published in Sleep showed that adults in midlife who had symptoms of insomnia and slept less than 6 hours a night were more likely to have cognitive impairment. The results may help healthcare providers understand which individuals are at increased risk of cognitive decline and dementia.&
- Vascular Diseases May Be Associated with Severe COVID-19https://practicalneurology.com/news/vascular-diseases-may-be-associated-with-severe-covid-19/2469353/Although COVID-19 was initially thought to be an infectious disease of the lungs, vascular inflammation and heart injury appear to be common features, occurring in 20% to 30% of hospitalized patients and contributing to 40% of deaths. The risk of death from COVID-19-related heart damage appears t
- Treatment with C5 Inhibitor Associated with Significant, Clinically Meaningful Improvements in Generalized Myasthenia Gravis Disease Severityhttps://practicalneurology.com/news/treatment-with-c5-inhibitor-associated-with-significant-clinically-meaningful-improvements-in-generalized-myasthenia-gravis-disease-severity/2476040/Treatment with gefurulimab (Alexion Pharmaceuticals, Boston, MA), an investigational complement C5 inhibitor, was associated with significant and clinically meaningful improvements in disease severity for adults with anti-acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG)
- Washout Period Following Dimethyl Fumarate Treatment Cessation Associated with MS Disease Activity and Relapsehttps://practicalneurology.com/news/washout-period-duration-following-dimethyl-fumarate-treatment-cessation-associated-with-ms-disease-activity-and-relapse/2470484/According to results presented at the 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), disease activity was significantly associated with the duration of the interval between cessation of dimethyl fumarate (DMF) treatment and the initiation of an alternative disease-mod
- Long-Term Use of Proton Pump Inhibitors Associated with Significantly Increased Risk of Dementiahttps://practicalneurology.com/news/long-term-use-of-proton-pump-inhibitors-associated-with-significantly-increased-risk-of-dementia/2470266/Long-term, cumulative proton pump inhibitor (PPI) usage was associated with a significantly increased risk of dementia according to study results published in Neurology. During follow up, study participants who used
- Sleep-Disordered Breathing Associated with Brain Atrophy in Amyloid-Positive, Cognitively Unimpaired Individualshttps://practicalneurology.com/news/sleep-disordered-breathing-associated-with-brain-atrophy-in-amyloid-positive-cognitively-unimpaired-individuals/2470258/Research published in Neurology has identified an association between sleep-disordered breathing (SDB), such as sleep apnea, and atrophy of the medial temporal lobe (MTL) in amyloid-positive, cognitively unimpaired i
- American Heart Association Presidential Advisory Adds Sleep as Key Metric for Cardiovascular Healthhttps://practicalneurology.com/news/american-heart-association-presidential-advisory-adds-sleep-as-key-metric-for-cardiovascular-health/2469957/In a new Presidential Advisory from the American Heart Association (AHA), sleep duration has been added as an essential component for ideal heart and brain health. The update to this advisory was prepared by a volunteer wr
- GAIN Study Tests Gum Disease-Associated Protein as Target for Disease-Modifying Treatment of Alzheimer Diseasehttps://practicalneurology.com/news/gain-study-tests-gum-disease-associated-protein-as-target-for-disease-modifying-treatment-of-alzheimer-disease/2469650/Characteristics of the study design and population for the ongoing phase 2/3 GAIN trial (NCT03823404) of atuzaginstat (COR338; Cortexyme, South San Francisco, CA) were presented at the Alzheimer Association International Conference Jul